SyncMedical LLC.

Best news in a long time ! The U.S. FDA has approved the emergency authorization use of Pfizer’s inhibitor of the SARS-CoV-2 novel main protease (Mpro). The therapy is authorized for use in high-risk individuals of 12 years and older. Paxlovid contains two oral drugs, one (nirmatrelvir) blocking the viral protease, and a second one (ritonavir) enhancing the half-life of the SARS-CoV-2 inhibitor. Paxlovid is positioned to play a key role in the pandemic, at a time when the Omicron variant is escaping neutralization by vaccine and convalescent antibodies, and the only treatments available have limited therapeutic effects, or their availability is limited. Only one of the three therapeutic antibodies in use in the U.S. (sotrovimab, by Glaxo -Vir Bio) is active against omicron, and its availability may be limited in the near future. Pfizer’s small-molecule inhibitor can be mass-produced, and will be a key therapy for immunocompromised individuals and others at high-risk of severe infection. FDA EUA letter available at https://lnkd.in/gzW2uewm

www.fda.gov

“harnessing the cutting-edge tech to minimise the hit-and-miss nature of R&D and discover new therapies with previously impossible speed and accuracy.”

https://www.pharmaceutical-technology.com/features/new-generation-ai-drug-discovery-companies/

Artificial intelligence: a new generation of drug discovery companies A growing number of pharmaceutical and biotech companies are harnessing the power of AI in drug discovery.

Available as a pre-print on medRxiv ahead of peer-reviewed publication, the study estimates the number of deaths from February through September 2020 above what would be expected in a normal year, or “excess deaths.” For every 100 excess deaths directly attributed to COVID-19, there were another 36 excess deaths. This means 26 percent of all excess deaths were not directly attributed to COVID.

https://www.bu.edu/sph/2020/10/01/us-covid-deaths-may-be-undercounted-by-36-percent/

US COVID Deaths May Be Undercounted by 36 Percent | SPH | Boston University For every 100 deaths officially attributed to COVID-19, there were also 36 additional deaths beyond what would be expected in a normal year—deaths directly or indirectly caused by the pandemic.

New Drug targeting
https://youtu.be/EMaKFcpV5wg

A new drug target in the fight against COVID-19 An international team of scientists led by Professor Christiane Schaffitzel from the University of Bristol’s School of Biochemistry and Professor Imre Berger...

https://medicalxpress-com.cdn.ampproject.org/c/s/medicalxpress.com/news/2020-09-discovery-druggable-pocket-sars-cov-spike.amp

Discovery of a druggable pocket in the SARS-CoV-2 Spike protein could stop virus in its tracks A druggable pocket in the SARS-CoV-2 Spike protein that could be used to stop the virus from infecting human cells has been discovered by an international team of scientists led by the University of Bristol. The researchers say their findings, published today in the journal Science, are a potential....